Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid

Swinkels, O.Q.J.; Prins, M.; Kucharekova, M.; Boo, Theo de; Gerritsen, Marinel; Valk, P.G.M. van der; Kerkhof, P.C.M. van de

doi:10.1046/j.1365-2133.2002.04698.x

Cited by 22 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Swinkles et al (EG B) performed a study on the efficacy of monotherapy with 5 ϫ/weekly clobetasol applied to three plaques per patient versus 1 ϫ/daily dithranol or 5 ϫ/weekly combination use of dithranol and clobetasol [104]. Each monotherapy resulted in complete remission in 80 % of plaques, while combination therapy achieved full remission in 100 %.…”

Section: Dithranol and Topical Steroidsmentioning

confidence: 99%

“…For dithranol monotherapy, there was one grade A 2 study [96], 11 grade B studies [97][98][99][100][101][102][103][104][105][106][107], and 1 grade C study [108]. For dithranol monotherapy, there was one grade A 2 study [96], 11 grade B studies [97][98][99][100][101][102][103][104][105][106][107], and 1 grade C study [108].…”

Section: Efficacymentioning

confidence: 99%

“…Ten grade A 2 studies on topical steroid monotherapy were included [116][117][118][119][120][121][122][123][124][125], 17 grade B studies [104,[126][127][128][129][130][131][132][133][134][135][136][137][138][139][140][141], and two grade C studies [142,143]. Ten grade A 2 studies on topical steroid monotherapy were included [116][117][118][119][120][121][122][123][124][125], 17 grade B studies [104,[126][127][128][129][130][131][132][133][134]…”

Section: Efficacymentioning

confidence: 99%

See 2 more Smart Citations

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

Nast

Boehncke

Mrowietz

et al. 2011

J Deutsche Derma Gesell

155

View full text Add to dashboard Cite

Section: Dithranol and Topical Steroidsmentioning

confidence: 99%

Section: Efficacymentioning

confidence: 99%

Section: Efficacymentioning

confidence: 99%

See 1 more Smart Citation

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

Nast

Boehncke

Mrowietz

et al. 2011

J Deutsche Derma Gesell

155

View full text Add to dashboard Cite

“…The efficacy of dithranol in combination with an ultrapotent topical corticosteroid (clobetasol propionate) was studied during a treatment of 39 days using an intra-individual comparison between (1) dithranol short-contact treatment with daily applications of clobetasol-17-propionate ointment and (2) daily applications of clobetasol-17-propionate ointment only. Dithranol in combination with clobetasol-17-propionate showed a better and faster clearing response and the subsequent remission periods were more prolonged [12].…”

Section: Combinationsmentioning

confidence: 99%

The Topical Treatment of Psoriasis

Kerkhof

Vissers

2003

Skin Pharmacol Physiol

Self Cite

View full text Add to dashboard Cite

According to the patients, improvement of efficacy, long-term safety and improvement of compliance are needed. The topical treatment has been innovated during the last decade. Most important are the introduction of two new classes of treatments: topical vitamin D₃ analogues and the retinoid tazarotene. To what extent, however, have we achieved developments which are in line with the needs as expressed by the patients? Improved efficacy has been realized by successful combinations of topical treatments. In particular, the combinations of dithranol, vitamin D₃ and tazarotene with a topical corticosteroid proved to be very effective with a reduced profile of side-effects. The efficacy of vitamin D₃ analogues and tazarotene is such that the efficacy of a potent corticosteroid (betamethasone-17-valerate) is approached; calcipotriol even showed an efficacy which is at least as good as this corticosteroid. The long-term safety of new compounds has been evaluated for at least 12 months in large studies. Remarkably for corticosteroids such information is available for only 12 weeks. However, intermittent applications of a topical corticosteroid in combination with another topical treatment provide an effective and safe long-term control of psoriasis. Compliance is a conditio sine qua non for an effective topical treatment. Important progress has been made to increase compliance. Short-contact dithranol has been popularized as an ambulatory treatment which is a highly effective approach as a care instruction programme. Formulations which are better from a cosmetical point of view have been developed for various topical treatments. Reduction of the frequency of applications proved to be possible for most treatments. Once daily applications for corticosteroids, vitamin D₃ analogues and retinoids have been developed, and intermittent applications, a few times per week, are possible for corticosteroids, which proved to be very effective with a reduced profile of side-effects, and are also developed for dithranol.

show abstract

“…Analysing several statistical parameters the authors concluded that intermittent addition of clobetasol-17-propionate ointment enhanced the antipsoriatic efficacy of short-contact, highdose dithranol therapy in terms of clearing capacity and treatment duration, without shortening remission duration. 66 A prospective, single-center, open-label, right/left comparison of 28 lesion pairs in 15 patients was conducted by Bowman et al They treated psoriasis patients for a 2-week period, followed by a 4-week post-treatment observation phase. Calcipotriene-and tazarotene-treated lesions showed nearly identical efficacy with their matched clobetasoltreated counterparts but erythema improved significantly more in clobetasol-treated lesions (P  0.05).…”

Section: 52mentioning

confidence: 99%

Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate

Zampetti

Feliciani

Tulli

et al. 2010

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Clobetasol-17 propionate is a dihalogenated corticosteroid which, on the basis of the vasoconstrictor assay, is classified as the most potent of all topical steroids. Since 1973 it has been marketed specifically for the short term topical treatment of moderate and severe cortico-responsive dermatoses for its antinflammatory, immunosuppressive and antimitotic effects. Psoriasis, atopic dermatitis, chronic eczema, boullous disorders and itching dermatosis of the genital area are usually well controlled by clobetasol with a great improvement of quality of life in patients. In this manuscript, we reviewed data concerning pharmacology, efficacy and safety profile of clobetasol-17 proprionate, updated studies on its use, efficacy of different formulations and impact on quality of life in corticosteroid-responsive dermatoses.

show abstract

Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid

Abstract: Intermittent addition of clobetasol-17-propionate ointment enhanced the antipsoriatic efficacy of short-contact, high-dose dithranol therapy in terms of clearing capacity and treatment duration, without shortening remission duration.

Cited by 22 publications

References 8 publications

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

S3 – Guidelines on the treatment of psoriasis vulgaris Update 2011

The Topical Treatment of Psoriasis

Pharmacotherapy of Inflammatory and Pruritic Manifestations of Corticosteroid-Responsive Dermatoses Focus on Clobetasol Propionate

Contact Info

Product

Resources

About